Patent · US Expired

(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

US7098230B2 · kind B2 · utility

13Cited by

34References

23Claims

0Family size

Assignee

Dov Pharmaceutical · US

Inventors

Arnold Lippa · Franklin Lakes, US
Joseph W. Epstein · Rochester, US

Key dates

Filing date	Jan 23, 2004
Grant date	Aug 29, 2006
Priority date	—
Expiry date	Jan 23, 2024

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D209/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.